Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INV-8989 in KRAS G12D-mutant advanced solid tumors
CTR20261696Phase 2Active
- Sponsor
- Guangdong Institute of Innovative Drug Translational Medicine
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of INV-8989 in Nonhematologic neoplasms, sponsored by Guangdong Institute of Innovative Drug Translational Medicine. Started Jun 2026; status: active.
02
Drugs
INV-8989
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20261696.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261696.